Last reviewed · How we verify

Single Shot Femoral Nerve Blocks

Eastern Maine Medical Center · Phase 1 active Small molecule

Single Shot Femoral Nerve Blocks is a Small molecule drug developed by Eastern Maine Medical Center. It is currently in Phase 1 development. Also known as: 0.5% ropivacaine.

At a glance

Generic nameSingle Shot Femoral Nerve Blocks
Also known as0.5% ropivacaine
SponsorEastern Maine Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Single Shot Femoral Nerve Blocks

What is Single Shot Femoral Nerve Blocks?

Single Shot Femoral Nerve Blocks is a Small molecule drug developed by Eastern Maine Medical Center.

Who makes Single Shot Femoral Nerve Blocks?

Single Shot Femoral Nerve Blocks is developed by Eastern Maine Medical Center (see full Eastern Maine Medical Center pipeline at /company/eastern-maine-medical-center).

Is Single Shot Femoral Nerve Blocks also known as anything else?

Single Shot Femoral Nerve Blocks is also known as 0.5% ropivacaine.

What development phase is Single Shot Femoral Nerve Blocks in?

Single Shot Femoral Nerve Blocks is in Phase 1.

Related